3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 527,656 | 833,883 |
売掛金 | 35,621 | 98,855 |
仕掛品 | 30,216 | 46,115 |
原材料及び貯蔵品 | 43,783 | 32,755 |
前渡金 | 9,102 | 28,820 |
未収還付法人税等 | 66,818 | - |
その他 | 104,570 | 65,266 |
流動資産合計 | 817,769 | 1,105,697 |
固定資産 | | |
有形固定資産 | | |
建物 | 254,674 | 254,674 |
減価償却累計額及び減損損失累計額 | △254,674 | △254,674 |
建物(純額) | - | - |
機械及び装置 | 3,165 | 2,358 |
減価償却累計額及び減損損失累計額 | △3,165 | △2,358 |
機械及び装置(純額) | - | - |
工具、器具及び備品 | 995,575 | 992,128 |
減価償却累計額及び減損損失累計額 | △995,575 | △992,128 |
工具、器具及び備品(純額) | - | - |
有形固定資産合計 | - | - |
投資その他の資産 | | |
差入保証金 | 49,505 | 49,505 |
投資その他の資産合計 | 49,505 | 49,505 |
固定資産合計 | 49,505 | 49,505 |
資産合計 | 867,275 | 1,155,203 |
負債の部 | | |
流動負債 | | |
未払金 | 139,436 | 161,334 |
契約負債 | 197,432 | 142,054 |
未払法人税等 | 2,425 | 2,160 |
その他 | 20,299 | 22,189 |
流動負債合計 | 359,593 | 327,738 |
固定負債 | | |
長期未払金 | 106,849 | 51,067 |
資産除去債務 | 47,165 | 47,286 |
固定負債合計 | 154,015 | 98,353 |
負債合計 | 513,608 | 426,091 |
純資産の部 | | |
株主資本 | | |
資本金 | 50,000 | 50,000 |
資本剰余金 | 26,322,132 | 27,516,414 |
利益剰余金 | △26,092,962 | △26,908,248 |
自己株式 | △2 | △4 |
株主資本合計 | 279,166 | 658,161 |
新株予約権 | 74,500 | 70,950 |
純資産合計 | 353,666 | 729,111 |
負債純資産合計 | 867,275 | 1,155,203 |
E0536345640オンコセラピー・サイエンス株式会社OncoTherapy Science, Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse456402025-03-31jpcrp_cor:ReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402024-03-31jpcrp_cor:ReportableSegmentsMember456402024-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402024-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember456402023-04-012024-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402023-04-012024-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402023-04-012024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402025-03-31jpcrp_cor:ReconcilingItemsMember456402024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember456402024-03-31jpcrp_cor:ReconcilingItemsMember456402023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember456402023-03-31jppfs_cor:ShareholdersEquityMember456402023-03-31jppfs_cor:RetainedEarningsMember456402023-03-31jppfs_cor:CapitalSurplusMember456402023-03-31jppfs_cor:CapitalStockMember456402025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-03-31jppfs_cor:ShareholdersEquityMember456402025-03-31jppfs_cor:RetainedEarningsMember456402025-03-31jppfs_cor:CapitalSurplusMember456402025-03-31jppfs_cor:CapitalStockMember456402024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402024-04-012025-03-31jppfs_cor:ShareholdersEquityMember456402024-04-012025-03-31jppfs_cor:RetainedEarningsMember456402024-04-012025-03-31jppfs_cor:CapitalSurplusMember456402024-04-012025-03-31jppfs_cor:CapitalStockMember456402024-03-31jppfs_cor:SubscriptionRightsToSharesMember456402024-03-31jppfs_cor:ShareholdersEquityMember456402024-03-31jppfs_cor:RetainedEarningsMember456402024-03-31jppfs_cor:CapitalSurplusMember456402024-03-31jppfs_cor:CapitalStockMember456402023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember456402023-04-012024-03-31jppfs_cor:ShareholdersEquityMember456402023-04-012024-03-31jppfs_cor:RetainedEarningsMember456402023-04-012024-03-31jppfs_cor:CapitalSurplusMember456402023-04-012024-03-31jppfs_cor:CapitalStockMember456402023-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-05-09456402025-03-31456402024-04-012025-03-31456402024-03-31456402023-04-012024-03-31456402023-03-31456402025-03-31jppfs_cor:TreasuryStockMember456402024-04-012025-03-31jppfs_cor:TreasuryStockMember456402024-03-31jppfs_cor:TreasuryStockMember456402023-04-012024-03-31jppfs_cor:TreasuryStockMember456402023-03-31jppfs_cor:TreasuryStockMemberxbrli:pureiso4217:JPY